Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
复制标题
DOI：
10.1007/s00432-012-1298-8
复制
发表时间：
2013-01
影响因子：
3.6
通讯作者：
Abdelhalim O
中科院分区：
文献类型：
--
作者：
El Ansary M;Mogawer S;Elhamid SA;Alwakil S;Aboelkasem F;Sabaawy HE;Abdelhalim O
树突状细胞(DC)可以作为潜在的细胞佐剂用于生产特定的肿瘤疫苗。我们的研究旨在评价自体脉冲DC疫苗在晚期肝细胞癌患者中的安全性和有效性，并与支持治疗进行比较。纳入30例不适合根治性或局部治疗的晚期肝癌患者。将患者分为2组，I组15例，接受成熟的自体DC体外冲击肝癌细胞株裂解液免疫接种。II组(对照组，编号15)接受支持性治疗。从每个患者的静脉血中提取104毫升以产生DC。用流式细胞仪检测CD80、CD83、CD86和人类白细胞抗原DR的表达来鉴定DC。分别于注射后3个月、6个月进行临床、放射学和实验室评估。观察到总体存活率的改善。放射学部分缓解2例(13.3%)，稳定病程9例(60%)，进展4例(26.7%)。DC注射后CD8+T细胞和血清干扰素-γ均升高。晚期肝癌患者的自体DC疫苗接种是安全和耐受性良好的。
Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines. Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done. Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8+ T cells and serum interferon gamma were elevated after DCs injection. Autologous DC vaccination in advanced HCC patients is safe and well tolerate.